Disease-modifying drugs for multiple sclerosis and infection risk: a cohort study.

José Maria Andreas WijnandsFeng ZhuElaine KingwellJohn David FiskCharity EvansRuth Ann MarrieYinshan ZhaoHelen Tremlett

Published in: Journal of neurology, neurosurgery, and psychiatry (2018)

Exposure to first-generation DMTs was not associated with an altered infection risk. However, exposure to the second-generation DMTs was, with natalizumab associated with a 59% increased risk of an infection-related physician claim. Continued pharmacovigilance is warranted, including an investigation of the DMT-associated infection burden on patient outcomes.

Keyphrases

multiple sclerosis
emergency department
primary care
risk factors
drug induced
electronic health record